Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026)
Ocugen's (OCGN) quarterly Net Income towards Common Stockholders came in at -$19.2 million in Q1 2026, down 24.93% YoY from -$25.5 million in Q1 2025, and down 24.93% on a QoQ basis from -$15.4 million in Q1 2025.
Analysis
Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$19.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 24.93% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.2 million (down 232.79% YoY) and the FY2024 annual result came in at -$44000.0, up 99.93% from the prior year.
- Net Income towards Common Stockholders retreated to -$19.2 million in Q1 2026, from -$15.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $40.1 million in Q4 2024 to a low of -$63.1 million in Q4 2023.
- A 5-year average of -$19.2 million and a median of -$21.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 187.52% — and 2024, when it surged 163.55%.
- Tracing OCGN's Net Income towards Common Stockholders over 5 years: stood at -$21.9 million in 2022, then slumped by 187.52% to -$63.1 million in 2023, then surged by 163.55% to $40.1 million in 2024, then tumbled by 138.29% to -$15.4 million in 2025, then declined by 24.93% to -$19.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$19.2 million (Q1 2026), -$15.4 million (Q1 2025), and $40.1 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | -24.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.88 Mn |
| Mar 31, 2026 | -19.18 Mn |
| Dec 31, 2025 | -17.71 Mn |
| Sep 30, 2025 | -20.05 Mn |
| Jun 30, 2025 | -14.74 Mn |
| Mar 31, 2025 | -15.35 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -10.29 Mn |
| Mar 31, 2024 | -11.92 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Sep 30, 2023 | -11.72 Mn |
| Jun 30, 2023 | -23.07 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |